Matrix metalloproteases and PAR1 activation.

Abstract

Cardiovascular diseases, including atherothrombosis, are the leading cause of morbidity and mortality in the United States, Europe, and the developed world. Matrix metalloproteases (MMPs) have recently emerged as important mediators of platelet and endothelial function, and atherothrombotic disease. Protease-activated receptor-1 (PAR1) is a G protein-coupled receptor that is classically activated through cleavage of the N-terminal exodomain by the serine protease thrombin. Most recently, 2 MMPs have been discovered to have agonist activity for PAR1. Unexpectedly, MMP-1 and MMP-13 cleave the N-terminal exodomain of PAR1 at noncanonical sites, which result in distinct tethered ligands that activate G-protein signaling pathways. PAR1 exhibits metalloprotease-specific signaling patterns, known as biased agonism, that produce distinct functional outputs by the cell. Here we contrast the mechanisms of canonical (thrombin) and noncanonical (MMP) PAR1 activation, the contribution of MMP-PAR1 signaling to diseases of the vasculature, and the therapeutic potential of inhibiting MMP-PAR1 signaling with MMP inhibitors, including atherothrombotic disease, in-stent restenosis, heart failure, and sepsis.

• Authors: Karyn M Austin, Lidija Covic, Athan Kuliopulos
• Journal: Blood (Blood) Vol. 121 Issue 3 Pg. 431-9 (Jan 17 2013) ISSN: 1528-0020 [Electronic] United States
• PMID: 23086754 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Receptor, PAR-1
• Matrix Metalloproteinases

Topics

• Animals
• Atherosclerosis (metabolism)
• Humans
• Matrix Metalloproteinases (metabolism)
• Receptor, PAR-1 (metabolism)
• Signal Transduction (physiology)
• Thrombosis (metabolism)